Ricevi le ultime notizie sulle azioni Bristol-Myers Squibb con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BMY

Ultime notizie per

BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

GSK Canada

Long Ideas

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

XRAY

I migliori analisti di Wall Street hanno espresso i loro pareri su azioni chiave nel settore sanitario. Ecco le loro raccomandazioni.

Rendimento del dividendo superiore al 4%: ecco quali titoli tenere d&#39;occhio

What Happened:

AAPL

AMZN

MSFT

Giornata decisiva per i mercati USA con cinque titoli al centro delle attenzioni e movimenti che fanno discutere analisti e investitori.

Azioni USA in primo piano: 5 titoli da seguire oggi sui mercati

Pfizer Covid shot

ABBV

Gli esperti puntano su tre colossi farmaceutici per una rendita passiva. L&#39;analisi dei titoli ad alto rendimento nel settore sanitario.

3 titoli a dividendo su cui scommettono i migliori analisti di Wall Street

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Press Releases

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Stopping Cancer Before It Spreads: The EMT Revolution in Oncology

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Bristol Myers Squibb Announces Dividend

Small Cap

Opinion

Advancing Cancer Research Brings New Hope for Patients Worldwide

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

AVAI

BNTX

CRSP

IOVA

OTLC

PPCB

RHHBY

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

Citigroup

Morgan Stanley

Wells Fargo

Cantor Fitzgerald

Jefferies

Screenshot 2025-09-23 at 9.53.22 PM

Biotech

Interview

RVPH

Reviva Pharmaceuticals CEO Tells Benzinga About The Trouble With Today&#39;s Schizophrenia Drugs – And How The Company Is Fixing That

Untitled design (12)

ACTU

INCY

Vexing challenges await cancer researchers every day — not just in finding new molecules — but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs.



Tumors have their own defense mechanisms, designed to thwart therapeutic intruders, and the immune system is often unable to mount an effective response. 

Comments

Bristol-Myers Squibb Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO